Cart is empty Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to treating schizophrenia, which affects an estimated 3.7 million American adults. The drug is now beginning to make its way into the hands of Washingtonians.
Leave A Comment